News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,024 Results
Type
Article (8037)
Company Profile (140)
Press Release (476750)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166853)
Career Advice (304)
Deals (25756)
Drug Delivery (7)
Drug Development (52875)
Employer Resources (15)
FDA (9762)
Job Trends (8577)
News (238311)
Policy (17900)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (490)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33200)
ALS (105)
Alzheimer's disease (976)
Antibody-drug conjugate (ADC) (264)
Approvals (10381)
Artificial intelligence (321)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6964)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (109)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (29)
Breast cancer (509)
Cancer (3651)
Cardiovascular disease (218)
Career advice (246)
Career pathing (1)
CAR-T (173)
Celiac Disease (1)
Cell therapy (477)
Cervical cancer (34)
Clinical research (47876)
Collaboration (1245)
Commercialization (3)
Compensation (1470)
Complete response letters (34)
COVID-19 (756)
CRISPR (63)
C-suite (750)
Cystic fibrosis (85)
Data (5661)
Denatured (4)
Depression (102)
Dermatology (62)
Diabetes (344)
Diagnostics (4186)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (155)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73738)
Editorial (1)
Employer branding (2)
Employer resources (15)
Events (87651)
Executive appointments (702)
FDA (12400)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (922)
Gene editing (125)
Generative AI (9)
Gene therapy (318)
GLP-1 (290)
Government (951)
Grass and pollen (2)
Guidances (281)
Healthcare (9337)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (157)
Infectious disease (944)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (255)
Interviews (42)
IPO (12395)
IRA (2)
Job creations (1972)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5209)
Licensing (8)
Liver cancer (44)
Longevity (17)
Lung cancer (509)
Lymphoma (251)
Machine learning (27)
Management (3)
Manufacturing (534)
Marketing (8)
MASH (118)
Medical device (8657)
Medtech (8802)
Mergers & acquisitions (14396)
Metabolic disorders (709)
mRNA (55)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (39)
Neuroscience (1826)
NextGen: Class of 2026 (3154)
Non-profit (846)
Obesity (225)
Opinion (10)
Ovarian cancer (158)
Pain (172)
Pancreatic cancer (197)
Parkinson's disease (201)
Partnered (12)
Patents (476)
Patient recruitment (508)
Peanut (31)
People (41279)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15470)
Phase 2 (21380)
Phase 3 (14401)
Pipeline (7342)
Policy (18)
Postmarket research (1572)
Preclinical (6541)
Press Release (34)
Prostate cancer (190)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (574)
Real estate (3025)
Recruiting (6)
Regulatory (14841)
Reports (21)
Research institute (583)
Resumes & cover letters (46)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (100)
Series A (158)
Series B (121)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2028)
Stomach cancer (3)
Supply chain (50)
Vaccines (322)
Venture capital (17)
Weight loss (73)
Women's health (79)
Date
Today (41)
Last 7 days (211)
Last 30 days (1576)
Last 365 days (19035)
2026 (12335)
2025 (19253)
2024 (22993)
2023 (26550)
2022 (34603)
2021 (37177)
2020 (33477)
2019 (23266)
2018 (17480)
2017 (18784)
2016 (17933)
2015 (24270)
2014 (21701)
2013 (18159)
2012 (20231)
2011 (20452)
2010 (20341)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (305)
Arkansas (11)
Asia (17903)
Australia (2100)
California (11984)
Canada (3148)
China (524)
Colorado (485)
Connecticut (409)
Delaware (208)
Europe (24769)
Florida (1789)
Georgia (380)
Hawaii (3)
Idaho (46)
Illinois (700)
India (51)
Indiana (314)
Iowa (15)
Japan (403)
Kansas (101)
Kentucky (30)
Louisiana (27)
Maine (26)
Maryland (1202)
Massachusetts (7862)
Michigan (308)
Minnesota (560)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (60)
New Jersey (2621)
New Mexico (12)
New York (2822)
North Carolina (1280)
North Dakota (4)
Northern California (6003)
Ohio (278)
Oklahoma (14)
Oregon (16)
Pennsylvania (2253)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4979)
Tennessee (120)
Texas (1942)
United States (38898)
Utah (360)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (929)
West Virginia (1)
Wisconsin (73)
Wyoming (1)
485,024 Results for "novozymes inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Legacy Novozymes delivers solid last full-year results
In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 25.4%, and ROIC including goodwill before special items* of 16.5%.
February 1, 2024
·
2 min read
Deals
Novozymes and Chr. Hansen announce name of future combined company; Novonesis
Novozymes and Chr. Hansen announced their future name ‘Novonesis’. The name reflects the beginning of an era of biosolutions where Novonesis will unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.
December 13, 2023
·
13 min read
Deals
The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner
On December 12, 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.
January 29, 2024
·
8 min read
Bio NC
Novozymes and Bactolife join forces to significantly reduce post weaning diarrhea and antibiotic use among weaner pigs
Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+.
September 4, 2023
·
3 min read
Business
Novozymes delivers stronger than expected Q1 results
In the first three months of the 2023 financial year, Novozymes delivers 5% organic sales growth, an EBIT-margin of 26.0% before special items, and ROIC including goodwill of 17.7% before special items.
April 26, 2023
·
4 min read
Bio NC
Novozymes accelerates growth in Q3 and is on track to deliver on full-year expectations
October 26, 2023. Novozymes delivers 5% organic sales growth, an EBIT-margin of 25.5% before special items, and ROIC including goodwill of 16.3% before special items in the first nine months of the 2023 financial year.
October 26, 2023
·
5 min read
Novozymes invests in new UV technology from Danish Lyras
The biotech group Novozymes has invested in a new and energy-friendly filtration replacement from Danish Lyras.
January 5, 2023
·
4 min read
Business
Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook
Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special items in the first half of the 2023 financial year.
August 9, 2023
·
5 min read
Business
Novozymes delivers historically strong full-year results
In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before special items* of 17.9%.
January 26, 2023
·
4 min read
Business
Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth
Novozymes, the world leader in biological solutions, and LinusBio, a leader in precision exposome sequencing, announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial.
November 10, 2022
·
4 min read
1 of 48,503
Next
